stockrowNexGel, Inc.
NXGL Healthcare Medical Instruments & Supplies
NexGel, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.4 million, up 31.5% from fiscal 2024.
- Revenue
- +27.8%
- EPS
- −344.4%
- Free cash flow
- −432.3%
- Total debt
- +353.8%
Quarter to June 2026, against a year earlier
Follow NXGL
Alert me
NexGel, Inc. (NXGL) EV/Sales
As of 5 November 2026, NexGel, Inc. (NXGL) trades at a EV/Sales of 0.3×. Over the past ten years it has ranged from −5.2× (March 2022) to 8.5× (December 2021); the current reading is higher than 17% of that period. That is below the Medical Instruments & Supplies industry median of 2.8× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.1× | (66.56%) |
| FY2024 | 3.2× | 25.51% |
| FY2023 | 2.6× | 344.05% |
| FY2022 | 0.6× | — |
| FY2021 | −3.4× | — |
| FY2020 | 8.5× | 0.00% |
| FY2019 | 8.5× | 0.00% |
| FY2018 | 8.5× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.5× | 19.26% |
| Mar 2026 | 0.5× | (57.83%) |
| Dec 2025 | 1.1× | (31.34%) |
| Sep 2025 | 1.6× | (7.32%) |
| 22 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| RVP Retractable Technologies, Inc. compare | −0.7× |
| RGNT Regentis Biomaterials Ltd. compare | n/m |
| CUPR Cuprina Holdings (Cayman) Limited compare | n/m |
| NXGL NexGel, Inc. | 0.3× |
| LUCY Innovative Eyewear, Inc. compare | 0.5× |
| BNGO Bionano Genomics, Inc. compare | 0.7× |
| NEPH Nephros Inc. compare | 1.4× |
| MLSS Milestone Scientific, Inc. compare | 2.8× |
| FEMY Femasys Inc. compare | 2.9× |
| Medical Instruments & Supplies industry median | 2.8× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)